There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and ...

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares ...

On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...

Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical, Inc.’s GMED growth in the third quarter can be attributed to the robust prospect in the musculoskeletal space. The company’s merger with NuVasive is expected to generate ...

Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Additionally, the company could be a top pick ...